Nexalis Therapeutics Limited has released a press release.
Sep23 Appendix 4C
Filed with ASX ·
On 6ix: 6ix.com/news/sep23-appendix-4c-1
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
Story so far
Earlier from Nexalis Therapeutics
- Quarterly Activities Report
- Quarterly Appendix 4C Cash Flow Report
- First Cohort Complete for Phase 1, Pain Indication IRX211
- First Patient Dosed for Phase 1, Pain Indication IRX211
- Ethics Approval for Phase 1 CRPS
Later from Nexalis Therapeutics
- Significant Milestone - Completion of IRX211 Phase 1 Trial
- IRX211 - Targeted Pain Indication Nomination - BTcP
- Dec23 Appendix 4C Cash Flow Report
- Dec23 Quarterly Activities Report
- Mar24 Quarterly Activities Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics